Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

G Protein-coupled Receptors

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Internal Receptors

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment of proximal and middle one-third humeral fractures with lateral distal tibial helical plate.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2016

Same author

MIF Plays a Key Role in Regulating Tissue-Specific Chondro-Osteogenic Differentiation Fate of Human Cartilage Endplate Stem Cells under Hypoxia.

Stem cell reports·2016

Same author

Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils.

Cancer cell·2016

Same author

Ultra-compact strain- and temperature-insensitive torsion sensor based on a line-by-line inscribed phase-shifted FBG.

Optics express·2016

Same author

The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up.

Chemical & pharmaceutical bulletin·2016

Same author

Increased Ubqln2 expression causes neuron death in transgenic rats.

Journal of neurochemistry·2016

Search research articles

Related Experiment Video

Updated: Mar 10, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Estrogen Receptor β as a Pharmaceutical Target.

Margaret Warner¹, Bo Huang¹, Jan-Ake Gustafsson²

¹Center for Nuclear Receptors and Cell Signaling, Department of Cell Biology and Biochemistry, University of Houston, Texas, USA.

Trends in Pharmacological Sciences

|December 17, 2016

Summary

Developing precise hormone therapies is crucial for maximizing health benefits and minimizing side effects. Selective targeting of hormone receptor subtypes, like estrogen receptor beta (ERβ), offers a promising approach for safer treatments.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Experiment Videos

Last Updated: Mar 10, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Area of Science:

Endocrinology
Pharmacology
Molecular Biology

Background:

Hormone therapies offer significant health benefits but often cause adverse effects.
Developing precise medicines to selectively target hormone actions remains a major clinical challenge.
This challenge is particularly relevant for nuclear receptor ligands, including hormones like estrogen.

Purpose of the Study:

To explore the potential of selective estrogen receptor beta (ERβ) targeting.
To investigate ERβ as a precise therapeutic target for various conditions.
To reduce side effects associated with traditional hormone therapies.

Main Methods:

Focus on selective targeting of estrogen receptor beta (ERβ) subtypes.
Review of current research on ERβ's role in hormone replacement and cancer.
Analysis of strategies for harnessing ERβ's beneficial effects while mitigating risks.

Main Results:

Selective targeting of ERβ presents a viable strategy for hormone therapy.
ERβ shows promise as a target for hormone replacement therapy.
ERβ is a potential target for treating breast and prostate cancers.

Conclusions:

Selective targeting of ERβ is a key strategy for developing precise endocrine medicines.
ERβ-selective therapies could offer improved treatment outcomes with fewer side effects.
Further research into ERβ modulation holds significant therapeutic potential in endocrinology and oncology.